An Open-label Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' Inactivated Poliomyelitis Vaccine Poliorix Administered as a Booster Dose at 18-24 Months of Age in Healthy Toddlers in China.

Trial Profile

An Open-label Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' Inactivated Poliomyelitis Vaccine Poliorix Administered as a Booster Dose at 18-24 Months of Age in Healthy Toddlers in China.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Poliovirus vaccine inactivated (Primary)
  • Indications Poliomyelitis
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 09 Dec 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
    • 09 Dec 2009 Actual initiation date (Jun 2009) added as reported by ClinicalTrials.gov.
    • 15 Aug 2009 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top